drugset / Trial / NCT05270772
CAR-T-19 Cells for Patients With CD19+ Relapse/Refractory B-ALL
NaSingle-groupOpen-labelTreatment
Summary
This is a single-arm, open-label phase I study to determine the safety, tolerability, and recommended dose (RD) of CAR-T-19 cells for patients with CD19+ relapse/refractory B-ALL under the age of 25.
Timeline
- Start
- 2021-02-25
- Primary completion
- 2022-07-15
- Completion
- 2024-09-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CART-19 cells | Cell therapy | 500000 cells/kg | Intravenous |
| Subject | CART-19 cells | Cell therapy | 1.5e+06 cells/kg | Intravenous |
| Subject | CART-19 cells | Cell therapy | 5e+06 cells/kg | Intravenous |